Clinical-stage pharmaceutical company Cempra has commenced a Phase III trial of its orally-administered fluoroketolide antibiotic candidate, solithromycin, designed to treat patients with community-acquired bacterial pneumonia (CABP).

The double-blind, global multi-centre and placebo-controlled study, which is expected to be completed in the first half of 2014, will enrol approximately 800 patients with PORT-II to PORT-IV CABP.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Patients will be randomised to receive either oral solithromycin, an 800mg loading dose followed by 400mg once daily for a total of five days, or once-daily oral administration of 400mg of moxifloxicin for seven days.

Non-inferiority of early response at 72 hours, as specified by the proposed FDA guidance, will be the primary endpoint of the study.

"The compound may offer both flexibility and convenience as it is in development for both oral and intravenous formulations."

Combination therapy with intravenous antibiotics or oral administration of fluoroquinolone antibiotics is the current therapy for moderate to moderately-severe CABP, according to the company’s president and CEO Prabhavathi Fernandes.

See Also:

The former involves intravenous therapy, possibly requiring hospital admission and the latter has been associated with significant side effects, possibly including Clostridium difficile infection due to the class’s broad activity spectrum.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Fernandes said the oral drug has also shown a favourable safety profile in over 400 patients, including when compared to levofloxacin in a Phase II trial in CABP patients.

"The compound may offer both flexibility and convenience as it is in development for both oral and intravenous formulations," Fernandes added.

"The drug may provide the option of IV-to-oral step down monotherapy to send patients home from the hospital sooner. In addition, and as this clinical trial may demonstrate, patients may be able to avoid hospital admission by starting on the oral form as monotherapy."